[Anti-inflammatory action of lipid-bound apoA-I cysteine mutants].
OBJECTIVE
To determine the anti-inflammatory functions of different cysteine mutants of apolipoprotein A-I recombinant HDLs.


METHODS
The recombinant HDLs (named rHDL52, rHDL107, rHDL173, rHDLwt) were reconstituted by mixing wild types or their mutants with dipalmitoyl phosphatidylcholine. And the in vivo effects on lipopolysaccharide (LPS)-induced endotoxemia were examined in mice. The plasma levels of plasma tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 in by ELISA were tested. And we also set up two control groups: LPS and saline.


RESULTS
The rHDL52 mice had a significant decrease of plasma TNF-alpha and IL-1beta and the protection of lung against acute injury. 24 h post-injection as compared with rHDLwt group [TNF-alpha: (135.28 +/- 12.84) pg/ml, IL-1beta: (82.00 +/- 8.19) pg/ml], the rHDL52 mice exhibited a higher capability of lowering the plasma levels of TNF-alpha and IL-1beta [(39.66 +/- 2.44) pg/ml, (66.83 +/- 6.24) pg/ml, both P < 0.05]. And, as indicated by histological sections of lung tissue, the rHDL52 mice could also lower the infiltration of inflammatory cells in lung.


CONCLUSIONS
rHDL52 has a higher anti-inflammation capability than wild type rHDLwt.
Wang
Yun-long
YL
Gout Laboratory, Affiliated Hospital, Medical College of Qingdao University, China.
Lu
Shu-lai
SL
Niu
Zhao-he
ZH
Miao
Zhi-min
ZM
Li
Xin-de
XD
Zhang
Yan-qiu
YQ
Li
Chang-gui
CG
Chen
Bao-sheng
BS
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D016632:Apolipoprotein A-I / Q000235:genetics / Q000494:pharmacology*; D003545:Cysteine / Q000235:genetics / Q000494:pharmacology*; D019446:Endotoxemia / Q000097:blood* / Q000473:pathology; D053583:Interleukin-1beta / Q000097:blood; D008070:Lipopolysaccharides; D008168:Lung / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009005:Monosaccharides; D009154:Mutation; D009842:Oligopeptides; D011994:Recombinant Proteins / Q000235:genetics / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000893:Anti-Inflammatory Agents; D016632:Apolipoprotein A-I; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D009005:Monosaccharides; D009842:Oligopeptides; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; C438940:lipid I; D003545:Cysteine